-
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia
-
iPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluation
-
T1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated consistent long-term insulin independence de-risking the combined technologies for both companies
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Sartorius collaborates with RoosterBio to advance downstream purification processes for the manufacture of exosomes
Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency.
FREDERICK, Md., Jan. 5, 2023 – The life science group Sartorius extended a strategic collaboration partnership agreement with RoosterBio Inc. (RoosterBio) to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency. [Read more…]
FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies
MADISON, WIS., January 5, 2023 – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases. [Read more…]
Cultivated Meat Market: Lab-Grown Meat Grows by Leaps and Bounds
Cultivated meat refers to meat created using cell culture techniques within a laboratory or manufacturing facility. It is produced by growing master cells collected from cattle, chicken, pigs, fish, lamb, and other livestock. Cultivated meat is ethically produced, because livestock is not used within the manufacturing processes beyond collecting the initial cells required for cell culture. [Read more…]
European Approval Makes Atara’s Ebvallo™ First Allogeneic T-Cell Therapy Approved Worldwide
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
Represents First Approval of an Allogeneic T-Cell Immunotherapy Globally
Pierre Fabre to Lead Commercialization and Distribution Activities in Europe
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 123
- Next Page »